Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Phase 1

Recruiting

Conditions: Pancreatic Cancer
Advanced Cancer
Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasms

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells
Drug: Anti-PD-1 monoclonal antibody

First Posted Date: 2019-10-31

Last Posted Date: 2023-09-01

Lead Sponsor: Changhai Hospital

Target Recruit Count: 30

Registration Number: NCT04146298

Locations: 🇨🇳
Changhai Hospital, Shanghai, China

Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

First Posted Date: 2019-10-22

Last Posted Date: 2020-09-04

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Registration Number: NCT04135092

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Phase 2

Withdrawn

Conditions: Allogeneic Stem Cell Transplant Recipient
Hematopoietic and Lymphoid Cell Neoplasm
Hematologic and Lymphocytic Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Fludarabine
Drug: Itacitinib
Drug: Methotrexate
Drug: Tacrolimus

First Posted Date: 2019-10-16

Last Posted Date: 2020-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT04127721

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Metastatic Melanoma
Pathologic Stage IIIC Cutaneous Melanoma AJCC V8
Pathologic Stage IV Cutaneous Melanoma AJCC V8
Recurrent Malignant Solid Neoplasm
Refractory Malignant Solid Neoplasm
Uveal Melanoma
Acral Melanoma
Neuroendocrine Tumors
Paraganglioma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Fludeoxyglucose F-18
Biological: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography

First Posted Date: 2019-10-08

Last Posted Date: 2024-12-11

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT04119024

Locations: 🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Phase 1

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Quizartinib
Drug: Fludarabine
Drug: Cytarabine
Drug: Idarubicin
Drug: glycosylated G-CSF

First Posted Date: 2019-10-02

Last Posted Date: 2022-03-14

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 63

Registration Number: NCT04112589

Locations: 🇪🇸
Hospital General Universitario de Alicante, Alicante, Spain
🇪🇸
Institut Català D'Oncologia-Hospital Germans Trias I Pujol, Badalona, Spain
🇪🇸
Institut Català D'Oncologia-Hospital Duran I Reynals, Bellvitge, Spain

and more 17 locations

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Phase 1

Terminated

Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions: Biological: MB-102
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2019-09-30

Last Posted Date: 2024-07-22

Lead Sponsor: Mustang Bio

Target Recruit Count: 3

Registration Number: NCT04109482

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Non-Viral TCR Gene Therapy

Phase 2

Withdrawn

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Endocrine/Neuroendocrine
Gastrointestinal/Genitourinary Cancers
Ovarian Cancer

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Aldesleukin
Biological: Sleeping Beauty Transposed PBL

First Posted Date: 2019-09-25

Last Posted Date: 2024-03-12

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04102436

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation

Phase 1

Active, not recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: Busulfan 3.2 mg/kg/day
Drug: Fludarabine
Drug: Melphalan
Drug: Antithymocyte globulin (ATG)
Drug: Busulfan 0.8 mg/kg
Procedure: Allogeneic hematopoietic cell transplantation (Allo-HCT)

First Posted Date: 2019-09-23

Last Posted Date: 2024-06-27

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 39

Registration Number: NCT04098393

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Phase 1

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Genetic: ALLO-715
Biological: ALLO-647
Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Nirogacestat

First Posted Date: 2019-09-18

Last Posted Date: 2023-08-14

Lead Sponsor: Allogene Therapeutics

Target Recruit Count: 132

Registration Number: NCT04093596

Locations: 🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 8 locations

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Phase 1

Withdrawn

Conditions: Hepatocellular Carcinoma
Hepatoblastoma

Interventions: Genetic: TEGAR T cells
Drug: Cytoxan
Drug: Fludarabine

First Posted Date: 2019-09-18

Last Posted Date: 2020-05-20

Lead Sponsor: Baylor College of Medicine

Registration Number: NCT04093648

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy